Abstract：
BACKGROUND: Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC). Over the past decade, the management of NSCLC-carrying EGFR mutation has evolved considerably with the use of tyrosine kinase inhibitors (TKIs). The main objective of this retrospective study was to analyze the evolution of therapeutic strategies in a cohort of patients with metastatic or locally advanced EGFR- mutated NSCLC.
METHODS: Data on patients with EGFR-mutated NSCLC, eligible for TKIs, and treated between 2010 to 2019 were collected. The main therapeutic strategies adopted following progression under TKIs and the prognostic factors for survival were analyzed.
RESULTS: The median age of the 177 patients was included in the cohort was 70years. The majority of patients (77.4%) received TKIs as first-line treatment, while 16.4% received chemotherapy. Osimertinib initiation as second-line treatment was a factor for better prognosis (OR=0.5). Finally, change of chemotherapy line was the main therapeutic strategy adopted for 41.3% of the patients having relapsed under TKIs.
CONCLUSIONS: Therapeutic management of EGFR-mutated NSCLC patients was in accordance with regional, national and international recommendations. The characterization of progression under TKI therapy has become systematic, allowing better adaption of therapeutic strategies.
METHODS: Data on patients with EGFR-mutated NSCLC, eligible for TKIs, and treated between 2010 to 2019 were collected. The main therapeutic strategies adopted following progression under TKIs and the prognostic factors for survival were analyzed.
RESULTS: The median age of the 177 patients was included in the cohort was 70years. The majority of patients (77.4%) received TKIs as first-line treatment, while 16.4% received chemotherapy. Osimertinib initiation as second-line treatment was a factor for better prognosis (OR=0.5). Finally, change of chemotherapy line was the main therapeutic strategy adopted for 41.3% of the patients having relapsed under TKIs.
CONCLUSIONS: Therapeutic management of EGFR-mutated NSCLC patients was in accordance with regional, national and international recommendations. The characterization of progression under TKI therapy has become systematic, allowing better adaption of therapeutic strategies.
摘要：
背景：表皮生长因子受体（EGFR）基因突变通常在非小细胞肺癌（NSCLC）中观察到。在过去的十年里，随着酪氨酸激酶抑制剂(TKIs)的使用,对携带EGFR突变的NSCLC的治疗有了相当大的进展.这项回顾性研究的主要目的是分析转移性或局部晚期EGFR突变NSCLC患者队列中治疗策略的演变。
方法：EGFR突变非小细胞肺癌患者的数据，有资格获得TKIs，并在2010年至2019年期间进行了治疗。分析了在TKIs下进展后采取的主要治疗策略和生存的预后因素。
结果：纳入队列的177名患者的中位年龄为70岁。大多数患者（77.4%）接受TKIs作为一线治疗，16.4%接受化疗。奥希替尼开始作为二线治疗是预后更好的因素（OR=0.5）。最后,化疗线的改变是41.3%的TKIs复发患者采用的主要治疗策略.
结论：EGFR突变的非小细胞肺癌患者的治疗管理符合区域性，国家和国际建议。TKI治疗下的进展表征已经变得系统，允许更好地适应治疗策略。
方法：EGFR突变非小细胞肺癌患者的数据，有资格获得TKIs，并在2010年至2019年期间进行了治疗。分析了在TKIs下进展后采取的主要治疗策略和生存的预后因素。
结果：纳入队列的177名患者的中位年龄为70岁。大多数患者（77.4%）接受TKIs作为一线治疗，16.4%接受化疗。奥希替尼开始作为二线治疗是预后更好的因素（OR=0.5）。最后,化疗线的改变是41.3%的TKIs复发患者采用的主要治疗策略.
结论：EGFR突变的非小细胞肺癌患者的治疗管理符合区域性，国家和国际建议。TKI治疗下的进展表征已经变得系统，允许更好地适应治疗策略。
